635 results about "Intestinal mucosa" patented technology

A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

The invention relates to compositions and methods for the administration of therapeutic and / or diagnostic agents such as polypeptides to a mammal, and in particular, compositions suitable for oral administration. The invention provides polymeric particles, and in particular, nano / microparticles such as, but not limited to, microspheres and nanospheres, as well as methods of synthesizing them. The invention also provides methods of increasing the serum concentration of a therapeutic agent such as a polypeptide by orally administering polymeric particles comprising the therapeutic agent. The compositions of the invention allow the absorption of polypeptides through intestinal mucosa and intestinal cells and into the bloodstream of a mammal. The invention further provides a method of treating type II diabetes through the oral administration of compositions comprising insulin and also provides a related glucose-responsive insulin delivery system.

The invention relates to infant formula milk powder and a production method thereof. The infant formula milk powder contains nutrition constituents such as protein, fat, carbohydrate, vitamins, mineral elements and the like with content regulated by the national standards on infant foods. Moreover, whey peptides, collagen peptides and casein phosphopeptides are added in the milk powder. Since the three kinds of binding peptides are added, the invention has the advantages that the immunity of cesarean infants is improved and the disease resistance of the infants is enhanced; the digestive function of the infants is improved, the intestinal mucosa proliferation is promoted and the digestive function is improved; and the development of the nervous system is promoted, the nutrition supply to the nervous system is guaranteed and the memory and the learning ability of the infants are improved.

The invention discloses small molecule polypeptide Ca-chelate of fishbone, which belongs to the field of functional food or additive. The method for preparing the small molecule polypeptide Ca-chelate of the fishbone comprises the following steps: boiling the fishbone at high temperature and high pressure; pulping to obtain the fishbone paste; utilizing the compound protease to execute enzymolysis; centrifuging to obtain the liquid supernatant and the sediment; filtering the liquid supernatant to obtain the small molecule polypeptide liquid of the fishbone; executing the composite acid acidification through citric acid and lactic acid for the sediment so as to obtain the fishbone calcium liquid; mixing the small molecule polypeptide liquid of the fishbone with the fishbone calcium liquid; executing the chelation at 40-50 degrees centigrade while the pH value is 7.5-8.5; and drying to obtain the small molecule polypeptide Ca-chelate of the fishbone. The invention has high Ca-chelate rate which reaches over 90%, and has high biological absorption rate of the calcium which reaches over 70%. The invention has no side effects, has good flavor, can be directly absorbed from intestinal mucosa after being eaten, solves the problems that the solubility of the traditional calcium source is bad, the absorption rate is low and the side effect is large, and solves the problem of producing calculi. In addition, the invention has a simple preparation method and low cost.

The invention specifically relates to a bifidobacterium microcapsule and a preparing method thereof. The bifidobacterium is obligatorily anaerobic and very sensitive to oxygen, PH, temperature, humidity, and other adverse external environment, thereby being very hard to remain activity during production, storage and transport; besides, if taken orally in a form of dry bifidobacterium powder, the bifidobacterium cannot tolerate low-pH value gastric acid, bile salt, and other environments, so a purpose that massive survived bifidobacteria arrive at an intestinal tract and colonise on the intestinal mucosa is hard to be guaranteed. The preparing method disclosed by the invention comprises the following steps of: adding freeze-dried bifidobacterium powder into a sodium alginate solution and then mixing in soybean oil, emulsifying the mixed solution and standing; centrifugally collecting micro-capsules; and drying the micro-capsules by using a vacuum freeze-drying technology. The bifidobacterium microcapsule disclosed by the invention has the advantages of gastric acid resistance, bile salt resistance and entericsolubility, high survival rate of bifidobacterium, simple preparation method, strong practicality, convenience for industrial production, and excellent storage stability and solves the problem of short storage period of probiotics preparations.

The invention discloses an anti-stress anti-diarrhea growth-promotion Chinese herbal medicine feed additive for a weaned pig, which is obtained by carrying out the superfine grinding and mixing on the following components at the mass ratio: 1-5 parts of Astragalus mongholicus, 1 part of Scutellaria baicalensis, 1 part of malt, 1 part of liquorice, 1-5 parts of dangshen, 1-5 parts of poria cocos and 1-5 parts of largehead atractylodes rhizome. According to the Chinese herbal medicine feed additive disclosed by the invention, the weaned pig growth performance can be improved, and the Chinese herbal medicine feed additive has the anti-diarrhea effect; the gastrointestinal tract development of the weaned pig can be promoted; the activity of the digestive enzyme of the gastrointestinal digestive tract of the wigged pig can be improved to promote the development of the pig digestive enzyme system; the micro-ecological environment of the digestive tract of the pig can be regulated and stabilized to accelerate the pig to grow; the antioxidation function of the wigged pig organism can be improved so as to improve the compensatory capability of the wigged pig organism on external irradiation; the intestinal mucosa form of the wigged pig can be improved so as to alleviate the intestinal villus withering of the wigged pig and promote the tract of the wigged pig to restore; and the immunologic function of the intestinal mucosa of the wigged pig can be regulated.

A method for treating obesity in a human patient is provided whereby an ablation source is introduced into the small intestine of the patient via a working channel of an endoscope, and the intestinal mucosa of the patient is ablated over a length of the small intestine in a range of approximately 40 cm to 100 cm.

The invention discloses a probiotic solid drink with a hypoglycaemic effect and a preparation method of the probiotic solid drink. The probiotic solid drink comprises components in percentage by weight as follows: 5%-15% of complex probiotics, 14%-28% of xylooligosaccharide, 50%-80% of L-arabinose and 4%-6% of dietary fiber. Complex probiotic powder contains lactobacillus rhamnosus, lactobacillus reuteri and bifidobacterium adolescentis. With the adoption of the probiotic solid drink, a large quantity of probiotics can be proliferated, the colonization rate and survival rate of exogenous probiotics on the intestinal mucosa are increased, a balanced system of intestinal flora is improved, immunity of a human body is improved, an organism is promoted to repair various functions, so that the auxiliary hypoglycaemic effect is realized. With the adoption of a dry blending technology, nutrient substances with different characteristics are subjected to optimizing and compounding combination, so that the problems of need for refrigeration, short guarantee period, single flora constitution, low viable counts and the like of a conventional liquid probiotic drink are solved, and the market prospect of products is broad.

The invention discloses a lactobacillus fermentum and an application thereof. The lactobacillus fermentum HAFI5007 is preserved in the China General Microbiological Culture Collection Center on March 11, 2011 and the registration number of the lactobacillus fermentum HAFI5007 is CGMCC No.4648. The lactobacillus fermentum is mainly utilized as an additive of animal feeds, can improve a nutrient digestibility, a microbial composition in a gastrointestinal tract, functions of intestinal mucous protein expression and intestinal mucosa immunization and an antioxidant defense system of a pig, and reduce oxidative damages produced by an oxidative stress. Therefore, the lactobacillus fermentum can improve a production performance of pigs.

The invention discloses a biological healthcare-type compound feed for soft-shelled turtles, wherein the material ingredients of the biological healthcare-type compound feed are as follows in percentage by mass: 30 to 40% of white fish meal, 10 to 20% of red fish meal, 4 to 10% of bulked bean pulp, 6 to 12% of yeast powder, 19 to 22% of starch a, 5 to 8% of fermented bean pulp, 2 to 5% of gluten powder, 2 to 5% of monocalcium phosphate, 0.05 to 0.3% of enzymic preparation, 0.1 to 0.3% of microbial preparation, 0.1 to 0.5% of compound vitamins, 1 to 3% of composite polymineral, 0.2 to 0.8% of 50% choline chloride, 0.1 to 0.5% of additive for protecting liver and gallbladder and 0.3 to 0.6% of additive for repairing intestinal mucosa. The feed has an increased feed utilization rate, and canbe used for improving the water body environment, reducing the disease occurrence and protecting the normal growth of the soft-shelled turtles, and thus, a high-quality and safe feed is provided for healthy cultivation.

The invention discloses a preparation method for separating biochemical medicaments from mucous membranes of porcine small intestines, in particular a preparation method for producing heparin sodium by using porcine small intestines. The preparation method for producing the heparin sodium by using the porcine small intestines is characterized by comprising the following steps of: preparing intestinal mucosa, and performing enzymolysis, adsorption, elution, precipitation, desalination, dehydration and drying to obtain the heparin sodium. The method has the advantages that: the heparin sodium has high yield, low activity loss and stable quality; the waste liquor is pollution-free in discharge and can be recycled; the problem of stench in a heparin sodium workshop is solved by adopting a workshop waste gas purification treatment device; and 2,000 to 2,400 pieces of porcine small intestines are needed for producing 0.1 billion units of heparin sodium by using the conventional process, only 1,400 to 1,600 pieces of porcine small intestines are needed for producing 0.1 billion units of heparin sodium by using the preparation method, and the effect and the activity of the heparin sodium are greatly improved, so that the production cost is greatly reduced, and the profit can be improved by over 40 percent.

The present invention provides a medicinal composition comprising (1) a pharmacologically active substance, (2) a drug absorbefacient and (3) a taurine compound or a polyamine. A taurine compound has an efect of suppressing or preventing damage of the intestinal mucous membrane, and therefore adding the taurine compound to a medicinal composition containing a pharmacologically active substance and a drug absorbefacient makes it possible to suppress or prevent damage of the intestinal mucosa. A polyamine improves the absorbability of pharmacologically active substances, and therefore adding the polyamine to a medicinal composition containing a pharmacologically active substance and a drug absorbefacient makes it possible to decrease the dose of the drug absorbefacient, thereby suppressing or preventing damage of the intestinal mucosa.

The invention relates to a hydrophobic drug containing polyelectrolyte complex, its preparation method and an application thereof. The polyelectrolyte complex is formed by static compounding of polycation and electronegative nanoparticles formed by polyanion or its derivative entrapment or linkage of a hydrophobic drug. The particle size of the polyelectrolyte complex is 20-500 nm. The positive / negative charge ratio of the polycation to the polyanion is between 1.2 and 6.0. According to the drug-containing complex formed by static compounding, an external positive charge shell can protect stability of the complex in a gastric acidic environment, and in an intestinal alkaline environment, the complex disintegrates and releases the internal anion drug loaded nanoparticles so as to promote absorption of the drug through intestinal mucosa. In addition, the polycation shell has mucosa adhesiveness and retention time of the drug in gastrointestinal mucosa can be prolonged. Therefore, the complex is suitable for oral administration of hydrophobic drugs. Bioavailability of the hydrophobic drugs is increased, and pains caused by injection delivery can be minimized for patients.

The invention relates to a method for extracting sodium heparin, which comprises the following steps: (1) enzymic hydrolyzing intestinal mucosa in a conventional method, and adopting enzyme preparation for the hydrolysis: mixture which is formed by mixing prolease, papain and lipase at a mass ratio of 1 to 4: 1 to 3: 0.1 to 0.3, and selecting the prolease from one of 2709 enzyme, AS1.398 enzyme and pancreatin; (2) resin adsorbing in a conventional method; (3) resin eluenting in a conventional method; (4) settling out the sodium heparin in a conventional method; (5) purifying the sodium heparin in a conventional method; (6) drying the sodium heparin in a conventional method to obtain the pure sodium heparin. An improved solution is characterized in that precipitator is added before filtering and hydrolyzing the mixture in the step 1. The method has simple process, short production period, simple and convenient operation and less investment, and is applicable to the industrialized mass production. The purity of the heparin can reach 100 to 120IU / mg, the extraction efficiency can reach 100 million IU / 1700 to 1800 chatterlings, the extraction efficiency can be improved by 20 to 30 percent, consumed salt can be reduced by 30 to 50 percent, water can be reduced by 50 to 70 percent, energy can be reduced by 30 to 40 percent, and the recycling rate of the crude protein can reach 60 percent.

The invention relates to a method for separating purified heparin sodium. Heparin sodium obtained through extracting porcine intestinal mucosa contains a great amount of protein, nucleic acid and other impurities, so that certain problems are brought to refining and purifying of heparin sodium. The traditional process method is that residual impurities are removed through a salt resolving process or an enzymolysis process, which has the disadvantages that the requirement on extraction quality of heparin sodium is high, the removal efficiency is relatively low, the follow-up oxidation precipitation refining time is long, the consumption of oxidant (hydrogen peroxide) is high, and the yield is low. According to the method provided by the invention, residual impurities in heparin sodium are removed with precipitant through enzymolysis, so that the process design is reasonable, the removal efficiency is high, the follow-up refining time is shortened, the product yield is improved, and the cost is lowered.

A method of providing a pet with a benefit relating to effective assimilation of a lipid is described wherein the pet is administered, as a part of, or in addition to its regular diet, an edible composition that contains intestinal mucosa function-promoters in an effective amount to maintain, improve or enhance the capacity of the pet to digest lipid efficiently. The invention extends to compositions for use in promoting lipid assimilation in pets, particularly senior or elderly pets. The compositions preferably include pancreatic, liver and intestinal mucosa function-promoters.

A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

The invention discloses a traditional Chinese medicinal feed additive for treating dysentery and diarrhea of livestock and poultry, which is prepared from the following raw material medicines: indigowoad root, pomegranate rind, rabdosia rubescens, amur corktree bark, baical skullcap root, golden thread, lightyellow sophora root, honeysuckle and dandelion. A preparation method for the traditional Chinese medicinal feed additive comprises the following steps of: respectively crushing the selected medicinal materials and mixing; or mixing and crushing. The selected raw material medicines are combined to achieve the effects of clearing heat and eliminating toxin, killing parasite and relieving itching, and astringing intestine and relieving diarrhea, can strengthen intestine to stop diarrhea, repair intestinal mucosa and improve the body resistance, and can quickly cure the dysentery, the diarrhea, inflammatorydiarrhea and stubborn diarrhea of livestock and poultry. Through application, the traditional Chinese medicinal feed additive has the advantages of good prevention and control effect, no toxic or side effect, readily available materials and low price.

The invention discloses compound probiotics and drug for treating ulcerative colitis and a preparation method thereof. The compound probiotics comprises Lactobacillus acidophilus CGMCC10436 and Lactobacillus plantarum CGMCC9961, and the drug for treating the ulcerative colitis adopts the two strains of the probiotics in a combined mode. According to the compound probiotics and drug for treating the ulcerative colitis and the preparation method thereof, Balb / c mice serve as test objects to establish an ulcerative colitis model, and the effect of the drug for resisting the ulcerative colitis is researched by starting from the angles such as apparent states and pathological conditions of the tested mice. It is shown through the test results that the drug has a good effect on resisting the ulcerative colitis, relapse of symptoms does not occur in a short period, the intestinal mucosa damage caused by the ulcerative colitis can be well repaired, and the drug for treating the ulcerative colitis can be widely applied to the field of preclinical medicine.

The invention discloses a composite type intestinal-health regulating agent for groupers. The composite type intestinal-health regulating agent comprises the following components in parts by weight: 5-10 parts of probiotic powder, 20-25 parts of fructooligosaccharide, 5-10 parts of tributyrin, 15-20 parts of glutamine, 10-20 parts of white carbon black and 15-45 parts of defatted rice bran. The invention also discloses a preparation method of the composite type intestinal-health regulating agent for the groupers. The composite type intestinal-health regulating agent has the advantages that the development of the intestines of the groups can be enhanced, the intestinal mucosal damage is restored, the immunologic function of the intestinal mucosa and the immunologic function of the system are activated, the balance of the intestinal flora is regulated, the health of the intestinal mucosa is maintained, and the morbidity of the enteritis is reduced. In addition, the activity of intestinal digestive enzyme can be improved, and the growth performance of the groupers and the feed utilization efficiency are improved.

The invention discloses a composite edible mushroom tablet and a production method thereof. The composite edible mushroom tablet comprises: 30-70 parts of edible mushrooms, 40-60 parts of sorbitol and 0-2 parts of magnesium stearate. The edible mushrooms are one or a plurality of materials from pleurotus citrinipileatus sing, agaricus blazei murill, armillaria mellea, hericium erinaceus, coprinus comatus, and grifola frondosa. By this way, the composite edible mushroom tablet is a compressed-tablet candy, and the composite edible mushroom tablet is convenient to eat, is rich in nutrition, can be easily absorbed by human bodies, can fully reflect the dietotherapy performance of the edible mushrooms, and has positive effects of anti-bacterium, improvement of immunity, promotion of blood circulation of gastric and intestinal mucosa, and other aspects. A production method of the composite edible mushroom tablet is shown as follows: cleaning one or the plurality of edible mushrooms, removing impurities, drying, crushing, weighing the sorbitol and the magnesium stearate according to a formula and mixing with each other, and then obtaining the candy through tablet compressing. The production method of the composite edible mushroom tablet has the advantage of simple operation.

The invention relates to a method for extracting a crude product of heparin sodium, which comprises the following steps of: firstly, taking the gut skin and the intestinal mucosa of a primitive gut as raw materials for extracting the heparin sodium, putting sodium chloride, sodium hydroxide and proteinase into an enzymolysis tank simultaneously according to a certain proportion and heating to carry out enzymolysis on the raw materials to form a liquid state; filtering, putting filtrate into an adsorption tank, eluting resin by brine after adsorbing the filtrate by adopting the higher resin, enabling the heparin sodium to enter eluent, putting the eluent into a depositing tank and depositing by alcohol; and drying and pulverizing. The invention has high efficiency, high stability, resource saving and high product yield and purity, is easy for large-scale production, can meet the requirements of markets at home and abroad to a crude product of heparin and has extensive application prospect.

The invention relates to active lactic acid bacteria capsules with a treatment and prevention effect on vaginitis. The lactic acid bacteria capsules capable of simultaneously adjusting dysbacteriosis of intestinal tracts and vagina and emphasizing treatment and prevention of the vaginitis are developed for achieving comprehensive effects. According to the technical scheme, excipient and lactic acid bacteria mixed bacteria powder are wrapped in the active lactic acid bacteria capsules with the treatment and prevention effect on vaginitis, and the lactic acid bacteria mixed bacteria powder comprises lactobacillus crispatus powder and other lactic acid bacteria subspecies powder with an effect of adjusting the intestinal flora. The active lactic acid bacteria capsules can be used for treating the vaginitis by adopting oral administration and intra-vaginal use; the oral lactobacillus can effectively improve the immunity of mucosa by stimulating the immune response of the intestinal mucosa, adjust the overall function state of a human body and well treat the vaginitis; and a large quantity of lactobacillus proliferated in the intestinal tract can inhibit growth of intestinal bacteria and reduce the risk of intestinal bacteria infection in vagina.

The invention provides a PED (Porcine Epedemic Diarrhea) inactivated vaccine and a preparation method thereof and relates to the field of biopharmacy. The PED inactivated vaccine comprises inactivated PEDV (Porcine Epedemic Diarrhea Virus), and is characterized in that the PED inactivated vaccine comprises 0.05-10 mg / mL Beta-glucosylceramide, 0.1-21 mg / mL monophosphoryl lipid A, 1.5-125 mg / mL muramyl dipeptide and 0.7-4.5 mg / mL Beta-glucan. According to the ingredients of the PED inactivated vaccine, Beta-glucosylceramide, monophosphoryl phosphoryl lipid A, muramyl dipeptide and Beta-glucan have the synergistic effect, the immune response of animals to antigens in the vaccine is significantly improved, the immune window phase is shortened, the antibody production duration of the animal body is obviously prolonged, the serum antibody level is improved, and the level of total intestinal mucosa secretory antibodies (the total SIgA) is improved.

The invention relates to a special clinical nutrient composition for an inflammatory bowel disease. The special clinical nutrient composition comprises protein, amino acid, peptides, fat, carbohydrate, dietary fibers, macro-elements, micro-elements, vitamins, dietary essence, medicinal and edible components, natural plant compounds and new resource food, wherein the dietary essence comprises millet powder, oat powder and apple powder, and the medicinal and edible components comprise lanceleaf lily bulbs, wild mint herbs, ural licorice roots, Indian bread, palmleaf raspberry fruits, barbary wolfberry fruits, king solomonseal rhizome and Chinese dates. A preparation method of the special clinical nutrient composition includes the steps: preparing the components into powder in advance and uniformly mixing the powder to prepare corresponding forms; performing water extracting concentration and freeze drying on the medicinal and edible components to prepare powder, microencapsulating the vitamins and the fat into powder and freeze-drying the dietary essence into powder. Compared with the prior art, the nutrient composition can provide needed energy, key nutrients and necessary micro-elements for a patient suffering from the inflammatory bowel disease, and improve blood sedimentation, C reactive protein and intestinal mucosa permeability symptoms of the patient.

The invention discloses a traditional Chinese medicine feed additive for treating animal dysentery and diarrhea. The selected traditional Chinese medicine raw materials include 8 parts of isatis root, 6 parts of scutellaria baicalensis, 6 parts of fried white peony root, 8 parts of the root of Chinese pulsatilla, 8 parts of amur corktree bark, 10 parts of sophora flavescens, 6 parts of Dabai, 8 parts of pomegranate rind, 6 parts of ash bark and 10 parts of radix astragali. A preparation method is characterized by grinding the selected raw materials and then mixing or mixing the materials and then grinding. The selected raw materials play roles of clearing away heat and toxic materials, getting rid of insects and stopping itching and relieving diarrhea with astringents together, can strengthen the intestines for relieving diarrhea, repair intestinal mucosa, enhance the disease-resistant capability of organisms and can rapidly cure animal dysentery and diarrhea, inflammatory diarrhea and intractable watery diarrhea. Through application, the feed additive is found to have the advantages of good prevention and treatment effects, no toxic or side effects, easily obtained raw materials and low price.

The invention discloses a compound feed for preventing soft-shelled turtle from the white abdominal shell disease. The compound feed comprises the following raw materials of both components and air dry matters by weight percent: 35-40 percent of imported white fish meal, 10-18 percent of steam brown fishmeal, 5-8 percent of soybean protein concentrate, 4-8 percent of fermented soybean meal, 3-6 percent of extruded soybean, 1-2 percent of wheat gluten, 4-8 percent of beer yeast, 18-23 percent of pre-gelatinized starch, 1-2 percent of calcium biphosphate, 0.3-0.6 percent of acid alkaline buffering agent, 0.03-0.08 percent of yeast culture, 0.1-0.4 percent of active strains preparation, 0.05-0.15 percent of sodium butyrate, 0.1-0.3 percent of compound Vitamin, 0.5-1.5 percent of complex ore and 0.2-0.5 percent of choline chloride. The feed provided by the invention can effectively keep the pH value in the intestinal canal of soft-shelled turtle to be stable and conditions the balance of intestinal flora, so that beneficial bacterium is in the ascendance in intestinal canal, the integrity and barrier action of intestinal mucosa are protected, and accordingly, the soft-shelled turtle is effectively prevented from the white abdominal shell disease.

The invention discloses a baking type suckling pig feed before weaning, consisting of materials in percentage by weight: 23-29.5 percent of corn flour, 26-36 percent of flour, 6-8 percent of extruded soybean flour, 3-5 percent of intestinal mucosa protein, 3 percent of sucrose, 3-3.5 percent of whey powder, 2-3 percent of fish meal, 6-9 percent of fermented soybean meal and 9-12 percent of dehulled soybean meal. The feed before weaning has the advantages of balanced nutrition and reasonable baking; and the disease resistance and the immunity of a suckling pig are improved.

Methods of treating adverse intestinal effects of a non-steroidal anti-inflammatory drugs (NSAID) in a subject by administering to the subject a therapeutically effective amount of a selective bacterial beta-glucuronidase inhibitor. The adverse intestinal effects to be treated include the formation or growth of an intestinal ulcer, increased intestinal permeability, the loss of intestinal villi, bleeding of the intestinal mucosa, and an increased intestinal inflammatory response. The methods are useful for treating the adverse effects of any NSAID such as propionic acid derivatives, carboxylic acid derivatives, enolic acid derivatives, fenamic acid derivatives, sulphonanilidies, and selective COX-2 inhibitors. The bacterial beta-glucuronidase inhibitors are selective for the inhibition of bacterial beta-glucuronidase enzymes and do not inhibit mammalian beta-glucuronidase.